Safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, physical examinations, and clinical laboratory tests [ Time Frame: Every 3 weeks from Baseline (Day 1) for up to 2 years ] [ Designated as safety issue: Yes ]

The incidence of adverse events will be tabulated and reviewed for potential significance and clinical Importance.

Dose-limiting toxicity and maximum tolerated dose of Urelumab (BMS-663513) as determined by the incidence of dose-limiting toxicities [ Time Frame: Every 3 weeks from Baseline (Day 1) for up to 9 weeks of therapy ] [ Designated as safety issue: Yes ]

Safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, physical examinations, and clinical laboratory tests [ Time Frame: 60 days after last dose of study therapy ] [ Designated as safety issue: Yes ]

The incidence of adverse events will be tabulated and reviewed for potential significance and clinical Importance

Dose-limiting toxicity and maximum tolerated dose of BMS-663513 as determined by the incidence of dose-limiting toxicities [ Time Frame: Up to 2 years if subject remains on study therapy ] [ Designated as safety issue: Yes ]

Area under the concentration-time curve in 1 dosing interval [AUC(TAU)] of Urelumab (BMS-663513) [ Time Frame: Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years ] [ Designated as safety issue: No ]

Plasma half-life (T-HALF) of Urelumab (BMS-663513) [ Time Frame: Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years ] [ Designated as safety issue: No ]

Total body clearance (CLT) of Urelumab (BMS-663513) [ Time Frame: Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years ] [ Designated as safety issue: No ]

Volume of distribution at steady-state (Vss) of Urelumab (BMS-663513) [ Time Frame: Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years ] [ Designated as safety issue: No ]

Human Anti-human Antibodies [ Time Frame: Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years ] [ Designated as safety issue: No ]

Tumor response and progression as determined by proportion of patients with best overall response (BOR), progression-free survival (PFS), objective response rate (ORR), time to response, and duration of response [ Time Frame: 9 weeks from Baseline (Day 1) and every 9 weeks until disease progression, death or last tumor assessment (Approximately up to 2 years) ] [ Designated as safety issue: No ]

Area under the plasma concentration-time curve from time 0 extrapolated to infinite time [AUC(INF)] of BMS-663513 [ Time Frame: Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years ] [ Designated as safety issue: No ]

Area under the concentration-time curve in 1 dosing interval [AUC(TAU)] of BMS-663513 [ Time Frame: Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years ] [ Designated as safety issue: No ]

Plasma half-life (T-HALF) of BMS-663513 [ Time Frame: Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years ] [ Designated as safety issue: No ]

Total body clearance (CLT) of BMS-663513 [ Time Frame: Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years ] [ Designated as safety issue: No ]

Volume of distribution at steady-state (Vss) of BMS-663513 [ Time Frame: Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years ] [ Designated as safety issue: No ]

Human Anti-human Antibodies [ Time Frame: Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years ] [ Designated as safety issue: No ]

Tumor response and progression as determined by proportion of patients with best overall response, progression-free survival, time to response, and duration of response [ Time Frame: Every 9 weeks until disease progression, death or last tumor assessment ] [ Designated as safety issue: No ]

The purpose of the study is to assess the safety, tolerability, pharmacokinetics and immunoregulatory activity of urelumab (BMS-663513) in cancer subjects with advanced and/or metastatic tumors and relapsed/refractory B-Cell Non-Hodgkin's Lymphoma

Subjects with advanced and/or metastatic solid tumors or B-NHL who are either refractory to or have relapsed from standard therapies, or for whom a standard therapy does not exist with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria

Life expectancy of 12 weeks or greater

Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

Adequate organ and marrow function

For certain subjects, willing and able to provide pre- and post-treatment fresh tumor biopsies

Age and Reproductive Status

Women of childbearing potential (WOCBP) and men must be using an acceptable method of contraception to avoid pregnancy throughout the study and for at least 4 weeks prior to initiation of dosing, and for at least 60 days after the last dose of investigational product in such a manner that the risk of pregnancy is minimized

WOCBP must have a negative serum or urine pregnancy test [minimum sensitivity 25 UI/L or equivalent units of human chorionic gonadotrophin (HCG)] within 24 hours prior to the start of investigational product

Women must not be breastfeeding

Exclusion Criteria:

Target Disease Exceptions

Subjects with known or suspected brain metastasis unless previously treated and without evidence of progression

Subjects with a history of prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured

Subjects with hepatocellular carcinoma

Medical History and Concurrent Diseases

Any active autoimmune disease or documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for subjects with vitiligo, psoriasis inactive within past 2 years, resolved childhood asthma/atopy, or thyroid disease controlled by replacement therapy without the need for immunosuppression

Any subject with the following reported drug-related adverse events on anti- Cytotoxic T-Lymphocyte Antigen 4 (anti-CTLA4) will not be permitted on study: hepatic, diarrhea/colitis or endocrine adverse events (AE)s Grade ≥ 2, any other non-laboratory immune-related AE ≥ Grade 3. Subjects must have minimum 9 week washout period between the last dose of anti-CTLA4 and the first dose Urelumab (BMS-663513)

Prior organ allograft or allogeneic bone marrow transplantation

Other Exclusion Criteria

Prisoners or subjects who are involuntarily incarcerated

Gender

Both

Ages

18 Years and older

Accepts Healthy Volunteers

No

Contacts ICMJE

Contact: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email: